1-(2-chloro-5-(trifluoromethyl)phenyl)-3-(4-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)phenyl)urea | 1347008-42-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2-chloro-5-(trifluoromethyl)phenyl)-3-(4-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)phenyl)urea
• 英文别名: 1-[2-chloro-5-(trifluoromethyl)phenyl]-3-[4-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxyphenyl]urea
• CAS: 1347008-42-7
• 化学式: C₂₃H₁₄ClF₆N₅O₂
• 分子量: 541.84
• InChiKey: AGSYMKDDKMWSAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  91.9
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  N-(4-((2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yl)oxy)phenyl)acetamide 在 硫酸 、 水 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 29.0h， 生成 1-(2-chloro-5-(trifluoromethyl)phenyl)-3-(4-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)phenyl)urea
  参考文献：
  名称：

  Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors

  摘要：

  A series of novel bis-aryl ureas containing trifluoromethyl imidazolyl group targeting Raf kinase were designed and synthesized based on the lead compound of Sorafenib. All the prepared compounds were evaluated for their in vitro antiproliferative activities against three human cancer cell lines including MDA-MB-231 (breast), BGC-823 (gastric), and SMMC-7721 (liver). Several compounds from the series exhibited excellent antitumor activities against all three tested cancer lines. Further their inhibitory activities against Raf kinase were investigated, and three compounds (11c, 11d, and 11p) demonstrated better activities than contrast drug Sorafenib. Especially compound 11c was found to be a potent and selective Raf kinase inhibitor and could be considered as a candidate compound for further development. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.05.051

文献信息

• Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors
  作者：Wenhu Zhan、Yanyang Li、Weiping Huang、Yanjin Zhao、Zhenglin Yao、Shanyou Yu、Shoujun Yuan、Falong Jiang、Shan Yao、Shuxin Li

  DOI：10.1016/j.bmc.2012.05.051

  日期：2012.7

  A series of novel bis-aryl ureas containing trifluoromethyl imidazolyl group targeting Raf kinase were designed and synthesized based on the lead compound of Sorafenib. All the prepared compounds were evaluated for their in vitro antiproliferative activities against three human cancer cell lines including MDA-MB-231 (breast), BGC-823 (gastric), and SMMC-7721 (liver). Several compounds from the series exhibited excellent antitumor activities against all three tested cancer lines. Further their inhibitory activities against Raf kinase were investigated, and three compounds (11c, 11d, and 11p) demonstrated better activities than contrast drug Sorafenib. Especially compound 11c was found to be a potent and selective Raf kinase inhibitor and could be considered as a candidate compound for further development. (C) 2012 Elsevier Ltd. All rights reserved.